Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
October 08 2021 - 5:30PM
Scopus BioPharma Inc. (Nasdaq:
“SCPS”), a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need, today announced that, on October 8,
2021, its 2021 Annual Meeting of Stockholders (the “Annual
Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday,
November 5, 2021, without any business being conducted, pursuant to
a Stipulation and Court Order approved by the Delaware Court of
Chancery between Scopus and Morris C. Laster, M.D. in connection
with Dr. Laster’s pending claims against Scopus in the Delaware
Court of Chancery. Notwithstanding the Stipulation and Court Order
requiring Dr. Laster to cause all shares of Scopus common stock
held by him to be present in person or by proxy at the Annual
Meeting and any adjournments thereof exclusively for the purposes
of establishing a quorum at the meeting, Dr. Laster failed to
satisfy this requirement by both not attending the Annual Meeting
in person and not making his shares present by proxy.
The adjourned meeting will be held by means of
remote communication and can be accessed via the following URL:
http://www.cesonlineservices.com/scps21_vm. The record date for the
Annual Meeting will remain August 16, 2021.
Scopus continues to solicit votes from its
stockholders with respect to the proposals set forth in Scopus’
proxy statement dated September 16, 2021. Proxies previously
submitted in respect of the Annual Meeting will be voted at the
adjourned Annual Meeting unless properly revoked, and stockholders
who have previously submitted a proxy or otherwise voted and who do
not want to change their vote need not take any action.
Scopus encourages all stockholders who own their
shares as of the close of business on August 16, 2021 who have not
yet voted to do so as soon as possible. Stockholders who have any
questions or require any assistance completing a proxy or voting
instruction form or who do not have the required materials, may
contact Scopus’ proxy solicitor, Morrow Sodali LLC, by calling
collect at (203) 561-6945 or toll-free at (800) 662-5200 or by
emailing SCPS@investor.morrowsodali.com.
About Scopus BioPharma
Scopus BioPharma Inc., both directly and through
subsidiaries, is a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need. The company’s lead drug candidate
is a novel, targeted immuno-oncology RNA therapy for the treatment
of multiple cancers. This drug candidate is highly distinctive,
encompassing both RNA therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor microenvironment.
Additional STAT3-targeting immunotherapy drug candidates include
bifunctional antisense and DNA-binding inhibition therapies. The
company is also seeking to develop additional drug candidates and
to identify additional compelling technologies for potential
acquisition, in-licensing and/or other similar transactions.
Receive updates by following Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to risks (including those
set forth in the company’s Form 10-K for the fiscal year ended
December 31, 2020, as amended, filed with the U.S. Securities and
Exchange Commission (“SEC”)) and uncertainties which could cause
actual results to differ from the forward-looking statements. The
company expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company’s
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections. Further,
there can be no assurance that the company will identify and/or
consummate any transaction relating to any additional
technologies.
Contacts
Rodd Leeds/David WaldmanCrescendo
Communications, LLCTel: (212) 671-1020Email:
SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas LeasureReevemarkTel: (212)
433-4600Email: scopus@reevemark.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024